Up-regulation of VANGL1 by IGF2BPs and miR-29b-3p attenuates the detrimental effect of irradiation on lung adenocarcinoma

Hao, Chuncheng; Xu, Cui‐yang; Zhao, Xinyu; Luo, Jianing; Wang, Gang; Zhao, Lihong; Ge, Xiaofeng

doi:10.1186/s13046-020-01772-y

Cited by 49 publications

(35 citation statements)

References 36 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The most frequently observed histological subtype of lung cancer is non-small cell lung cancer (NSCLC), which is primarily classified into squamous cell carcinoma (LUSC) and adenocarcinoma (LUAD) [ 2 ]. Despite new developments in cancer therapeutic treatments for LUAD in recent years, including surgical resection, immunotherapy, chemotherapy and radiotherapy, the prognosis of LUAD continues to be frustrating, and its 5-year survival is less than 20% [ 3 ]. Therefore, there is an urgent need to identify robust biomarkers for predicting the prognosis of LUAD patients.…”

Section: Introductionmentioning

confidence: 99%

A novel pyroptosis-related lncRNA signature for prognostic prediction in patients with lung adenocarcinoma

et al. 2021

View full text Add to dashboard Cite

Lung adenocarcinoma (LUAD) has been the major cause of tumor-associated mortality in recent years and has a poor prognosis. Pyroptosis is regulated via the activation of inflammasomes and participates in tumorigenesis. However, the effects of pyroptosis-related lncRNAs (PRlncRNAs) on LUAD have not yet been completely elucidated. Therefore, we attempted to systematically explore patterns of cell pyroptosis to establish a novel signature for predicting LUAD survival. Based on TCGA database, we set up a prognostic model by incorporating PRlncRNAs with differential expression using Cox regression and LASSO regression. Kaplan-Meier analysis was conducted to compare the survival of LUAD patients. We further simplified the risk model and created a nomogram to enhance the prediction of LUAD prognosis. Altogether, 84 PRlncRNAs with differential expression were discovered. Subsequently, a new risk model was constructed based on five PRlncRNAs, GSEC, FAM83A-AS1, AL606489.1, AL034397.3 and AC010980.2. The proposed signature exhibited good performance in prognostic prediction and was related to immunocyte infiltration. The nomogram exactly forecasted the overall survival of patients and had excellent clinical utility. In the present study, the five-lncRNA prognostic risk signature and nomogram are trustworthy and effective indicators for predicting the prognosis of LUAD.

show abstract

Section: Introductionmentioning

confidence: 99%

A novel pyroptosis-related lncRNA signature for prognostic prediction in patients with lung adenocarcinoma

et al. 2021

View full text Add to dashboard Cite

show abstract

“…Non-small cell lung cancer (NSCLC) is the most common histological type of lung malignancies, accounting for over 80% of all cases, and near half of NSCLC are lung adenocarcinoma (LUAD) (3,4). The prognosis of LUAD has been disappointing over the past two decades, with a five-year survival rate below 20% (5). Mortality from LUAD has decreased substantially in recent years, coinciding with the advances in immunotherapy.…”

Section: Introductionmentioning

confidence: 99%

Integrated Analysis of Cell Cycle–Related and Immunity-Related Biomarker Signatures to Improve the Prognosis Prediction of Lung Adenocarcinoma

Chen

Song

et al. 2021

Front. Oncol.

View full text Add to dashboard Cite

BackgroundLung adenocarcinoma (LUAD) is a leading malignancy and has a poor prognosis over the decades. LUAD is characterized by dysregulation of cell cycle. Immunotherapy has emerged as an ideal option for treating LUAD. Nevertheless, optimal biomarkers to predict outcomes of immunotherapy is still ill-defined and little is known about the interaction of cell cycle-related genes (CCRGs) and immunity-related genes (IRGs).MethodsWe downloaded gene expression and clinical data from TCGA and GEO database. LASSO regression and Cox regression were used to construct a differentially expressed CCRGs and IRGs signature. We used Kaplan-Meier analysis to compare survival of LUAD patients. We constructed a nomogram to predict the survival and calibration curves were used to evaluate the accuracy.ResultsA total of 61 differentially expressed CCRGs and IRGs were screened out. We constructed a new risk model based on 8 genes, including ACVR1B, BIRC5, NR2E1, INSR, TGFA, BMP7, CD28, NUDT6. Subgroup analysis revealed the risk model accurately predicted the overall survival in LUAD patients with different clinical features and was correlated with immune cells infiltration. A nomogram based on the risk model exhibited excellent performance in survival prediction of LUAD.ConclusionsThe 8 gene survival signature and nomogram in our study are effective and have potential clinical application to predict prognosis of LUAD.

show abstract

“…Sumo binding enzyme UBC9 regulates the SUMOylation of METTL3, controls homeostasis and promotes the accumulation of Snail, thus promotes the progression of HCC [ 105 ]. On the contrary, it is found that the expression of Snail mRNA decreases in the cells with SUMO mutant of METTL3 [ 106 ]. In addition, m6A can trigger the polysome mediated translation of Snail, which is in the CDS region of Snail instead of the 3’-UTR region, promote Snail transcription and participate in regulation EMT phenotype of tumor cells.…”

Section: The M6a and Transcription Factorsmentioning

confidence: 99%

“…The deletion of IGF2BP2/3 in m6A reader destroys the stability and expression of VANGL1 mRNA after radiation. Knockout VANGL1 can harm DNA from damage by activating BRAF-TP53BP1-Rad51 cascade, enhances the harmful effects of radiation on lung adenocarcinoma [ 106 ]. In cervical squamous cell carcinoma, FTO reduces β-catenin transcript, and promotes ERCC1 activity, thus enhancing chemo-radiotherapy resistance of cancer cells [ 162 ].…”

Section: Clinical Application Of M6a Methylation In Cancer Metabolismmentioning

confidence: 99%

The role of m6A RNA methylation in cancer metabolism

2022

View full text Add to dashboard Cite

Metabolic reprogramming is one of the main characteristics of malignant tumors, which is due to the flexible changes of cell metabolism that can meet the needs of cell growth and maintain the homeostasis of tissue environments. Cancer cells can obtain metabolic adaptation through a variety of endogenous and exogenous signaling pathways, which can not only promote the growth of malignant cancer cells, but also start the transformation process of cells to adapt to tumor microenvironment. Studies show that m6A RNA methylation is widely involved in the metabolic recombination of tumor cells. In eukaryotes, m6A methylation is the most abundant modification in mRNA, which is involved in almost all the RNA cycle stages, including regulation the transcription, maturation, translation, degradation and stability of mRNA. M6A RNA methylation can be involved in the regulation of physiological and pathological processes, including cancer. In this review, we discuss the role of m6A RNA methylation modification plays in tumor metabolism-related molecules and pathways, aiming to show the importance of targeting m6A in regulating tumor metabolism.

show abstract

Up-regulation of VANGL1 by IGF2BPs and miR-29b-3p attenuates the detrimental effect of irradiation on lung adenocarcinoma

Cited by 49 publications

References 36 publications

A novel pyroptosis-related lncRNA signature for prognostic prediction in patients with lung adenocarcinoma

A novel pyroptosis-related lncRNA signature for prognostic prediction in patients with lung adenocarcinoma

Integrated Analysis of Cell Cycle–Related and Immunity-Related Biomarker Signatures to Improve the Prognosis Prediction of Lung Adenocarcinoma

The role of m6A RNA methylation in cancer metabolism

Contact Info

Product

Resources

About